Interpretation 158
Tier 2|
|
|
Variants
Primary Sites
Tumor Types
Interpretation
Nonsynonymous mutations in the MET gene have been described in non-small cell lung cancer (NSCLC) and (small cell lung cancer) SCLC. Increased expression of MET protein was associated with improved progression free survival and overall survival in patients who received MetMAb (an anti-MET antibody) and erlotinib. The activity of MET inhibitors in NSCLC or SCLC tumors with non-kinase domain MET mutations is not yet known.
Citations
- Krishnaswamy et al Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer.Clin Cancer Res 2009;15(18) September 15, 2009
- Monica Kong-Beltran et al . Somatic Mutations Lead to an Oncogenic Deletion of MET in Lung Cancer. Cancer Res 2006; 66(1): 283-9
- Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors. Voortman J et al 2012 Current pharmaceutical design
- Neklason et al. BMC Cancer 2011, 11:424 Activating mutation in MET oncogene in familial colorectal cancer
- https://pct.mdanderson.org/genes/alterations?type=Germline&geneName=MET
Last updated: 2019-02-14 20:04:39 UTC